Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
about
Exploiting Genetic Interference for Antiviral TherapyResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsViral quasispecies evolutionDetection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.Viral Determinants of Resistance to Treatment in Patients with Hepatitis CReplicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-responseCharacterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In VitroAnalysis of Ribavirin Mutagenicity in Human Hepatitis C Virus InfectionEffects of Mutagenic and Chain-Terminating Nucleotide Analogs on Enzymes Isolated from Hepatitis C Virus Strains of Various GenotypesGenetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus RibavirinComparative Analysis of Nearly Full-Length Hepatitis C Virus Quasispecies from Patients Experiencing Viral Breakthrough during Antiviral Therapy: Clustered Mutations in Three Functional Genes, E2, NS2, and NS5aNaturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsCounteracting Quasispecies Adaptability: Extinction of a Ribavirin-Resistant Virus Mutant by an Alternative Mutagenic TreatmentEffect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In VivoMechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infectionsGenetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time.T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitroNaturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b.Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Host alternation of chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures.Evaluation of anti-HIV-1 mutagenic nucleoside analogues.Challenges for the development of ribonucleoside analogues as inducers of error catastrophe.Sequence diversity of hepatitis C virus: implications for immune control and therapy.Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsMutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency.Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.De novo initiation pocket mutations have multiple effects on hepatitis C virus RNA-dependent RNA polymerase activities.Emerging therapies for hepatitis C virus.Mechanism of action of ribavirin in the treatment of chronic hepatitis C.Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions.Selection of hepatitis C virus resistant to ribavirin.The role of HCV proteins on treatment outcomes.Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe.
P2860
Q24288775-66CD35CD-A288-434C-95A8-3B82D07C954DQ26777408-D32FAB81-B763-482F-AFA3-632B1CE28D85Q27013917-5DD78889-AF08-4A8D-9FE3-2AAEC6F9AE08Q27472717-339C89DA-A543-4287-A152-916081AC18A7Q27478062-432E8933-3B8F-45AE-B5E5-36668D8CF6E2Q27478215-7C12BE96-D3D0-44C6-9CC5-724143E0CA29Q27480361-97B6B32F-41B4-4D5C-917D-F54D1FD37707Q27480933-40C0386A-3F32-44C8-B04E-25AB26D14A24Q27486248-AE33B7F7-DBC3-4288-8DE8-85F6FCEC4766Q27486648-E2818BDF-FB1F-43A3-BFFD-128DF53C60F0Q27486924-C50636C9-841A-4D32-A605-D25AF50630C9Q27487949-CA5D0066-E8DC-4E7A-84E4-E795B15BB80CQ27488361-3D6D57CD-039A-4A7D-8934-B4BA999744B5Q27488394-7F784633-C691-4FD8-882D-DA4F80E5FF0FQ27490650-EC1F26BC-2626-4592-B180-7650963121FDQ28471847-CB39AC21-F458-42D4-A584-7A8975A4D297Q30402699-BADCB5B3-D393-41C9-96DC-BE961156E4ACQ30426020-516F150C-4E51-485D-9B66-642C5FCEF9FEQ31149778-37096EC7-4D7E-4E2E-BA80-72AA910711A8Q33782525-E7405318-3591-47E7-B003-634495A71741Q34409020-465C4118-E7E2-494A-A51A-C900DBBCE020Q34485363-DBC20B9A-DAEC-4AFE-8BB0-4003B24574CCQ34801497-847AF217-3D06-4AD9-B941-18A01BDCD026Q35742174-9E328CEE-2A5F-483F-AE51-A593838D2F15Q36179696-CB3650EA-8D83-4FBB-8BA4-E5E2523B2887Q36382719-F79F4141-6421-4144-A8C1-2207F0719494Q36399860-1608912F-4EA2-4436-93A1-B73574A98996Q36644831-016819FB-F2A4-4B4D-94D9-B84BFCBD6EB3Q36736898-17786296-418A-4A74-819F-10AAFC0D5AA1Q36827155-F1FC7B5E-354E-4F74-A642-E28809B7548AQ37263865-671F5889-3A73-4FC1-9703-1C4EDE672DDCQ37596636-307361DC-84D5-46FD-AF28-BC1C0F9168B0Q37772514-91FF9E72-9C78-4CCC-A415-D7DF443E012EQ37940977-A7505BA7-6839-42B2-B847-1854C75C170AQ38064285-2E8944FC-C702-4079-8B84-15E5BC5753BAQ38269623-FBCE7377-AAA0-42DB-BEFE-F4D4F1FCF2B1Q38668968-F616CFDC-901A-46F1-BECB-DED6F974FF42Q39376758-D5C1CEF6-3E08-4DF6-A2A9-9B0A3B636AB1Q39737884-B73D8F56-CB2D-48F7-A183-644C21CE06E4Q40199734-9EB843DA-BB65-4E62-8D28-1F743091B396
P2860
Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Identification of a ribavirin- ...... during ribavirin monotherapy.
@en
Identification of a ribavirin- ...... during ribavirin monotherapy.
@nl
type
label
Identification of a ribavirin- ...... during ribavirin monotherapy.
@en
Identification of a ribavirin- ...... during ribavirin monotherapy.
@nl
prefLabel
Identification of a ribavirin- ...... during ribavirin monotherapy.
@en
Identification of a ribavirin- ...... during ribavirin monotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Identification of a ribavirin- ...... during ribavirin monotherapy.
@en
P2093
Jian-Wen He
Karen L Lindsay
Ki-Jeong Lee
Kung-Chia Young
Susan L Milstein
Wen-Chun Liu
P2860
P304
P356
10.1002/HEP.1840380413
P407
P577
2003-10-01T00:00:00Z